worldwide offices | contact | help | sitemap

 

 

 

 

About Novartis Vaccines

About Novartis Vaccines

Patients

Novartis patient safety

Novartis puts patients first. We want to create value for all patients, including those who cannot afford treatment. In 2007 our access-to-medicines programs, valued at USD 937 million, reached 66 million patients globally. In the developing world, we extend free leprosy and tuberculosis treatment and offer our antimalarial drug Coartem without profit through multilateral institutions and public-private partnerships.

In the developed world we also provide discounts and assistance programs to patients who need support. We designed one of the most far-reaching patient-assistance programs ever implemented on a global scale for our cancer therapy Gleevec/Glivec.


Patient safety

To improve patient health and well-being, Novartis medicines must have the complete confidence of those who prescribe and use them. As a corporate citizen, we are committed to this goal.

Patients and healthcare-providers know that, beyond meeting regulatory requirements for product safety and efficacy, Novartis does everything possible to communicate concerns based on clinical trials and other research. Labels and package inserts often describe possible side effects and other risks, and provide directions for avoiding potential problems.

Novartis discloses data from our clinical trials no matter what the outcome. We assess safety concerns throughout the development of our products.

Ensuring patient safety does not end at product approval. We continue to assess risks or safety signals that emerge when a product is on the market. We work to find new and better ways to identify problems and communicate them as clearly as possible.

Our pharmacovigilance programs quickly identify, address and communicate new adverse events to regulatory agencies, including the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA), as well as to healthcare professionals and patients. We also work to protect patients from counterfeit products, which have created a growing concern around the world.

Responsible corporate citizenship is about open communication, going beyond the letter of the law and placing patients front and center in all our efforts. There is nothing more important than the safety of our products and those who use them.

 

Back to top

Meningitis disease

Meningitis disease

Fighting against meningitidis by finding novel treatments is one of Novartis Vaccines priority.

Culture & values

Culture & values

We provide medicines to treat and prevent diseases, ease suffering and improve quality of life.

About Novartis

About Novartis

We provide medicines to treat and prevent iseases, ease suffering and improve quality of life.